Basepoint Wealth’s AstraZeneca AZN Stock Holding History

Basepoint Wealth’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-126	Closed	-$23.1K	–	645
2025 Q4	$23.1K	Buy	+126	New	+$22.1K	0.01%	306

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Basepoint Wealth's AZN Position: Q1 2026 in Review

Basepoint Wealth sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 126 shares — an estimated $23.1K sold.

Basepoint Wealth first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $23.1K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Basepoint Wealth reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Basepoint Wealth sold 126 AstraZeneca shares in Q1 2026, an estimated $23.1K.
Basepoint Wealth first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
Basepoint Wealth's AstraZeneca position peaked at $23.1K in Q4 2025.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.